Experimental antibody 'cocktail' protects animals from three deadly Ebola viruses - Mapp Biopharmaceutical, Inc.

Mapp Biopharmaceutical

Press Inquiries

About Us
Product Development
News
- In the News
- Press Releases
Publications
Job Openings
Contact Us

antibody

Search for:

Archives

January 2021
June 2019
January 2019
September 2018

Categories

Press Releases

Recent News

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

Jan 13, 2021

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA and its partner Mapp Biopharmaceutical Inc. will explore the potential of a new monoclonal antibody (mAb) based therapeutic for Botulinum Neurotoxin...

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure

Jun 11, 2019

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure June 11, 2019 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and development contract for $16.5 million...

Additional Information

FCOI Policy
Purchase Order Terms and Conditions
Pay Transparency Nondiscrimination Provision
Equal Employment Opportunity is the Law
Institutional Biosafety Committee (NIH)
Employment of Individuals with Disabilities and Protected Veterans
Equal Employment Opportunity and Affirmative Action Policy Statement

Jobs Opportunities

© 2017-2021 Mapp Biopharmaceautical. All Rights Reserved.